Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1924 1
1940 1
1952 1
1954 1
1970 1
1975 1
1976 1
1977 1
1978 1
1982 1
1983 1
1984 2
1985 1
1986 1
1987 1
1990 1
1992 3
1993 1
1996 1
1997 2
1999 2
2000 3
2001 1
2002 8
2003 5
2004 3
2005 3
2006 4
2007 5
2008 9
2009 8
2010 10
2011 8
2012 13
2013 15
2014 17
2015 28
2016 36
2017 32
2018 26
2019 41
2020 49
2021 42
2022 44
2023 51
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

443 results

Results by year

Filters applied: . Clear all
Page 1
Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis.
Filliol A, Saito Y, Nair A, Dapito DH, Yu LX, Ravichandra A, Bhattacharjee S, Affo S, Fujiwara N, Su H, Sun Q, Savage TM, Wilson-Kanamori JR, Caviglia JM, Chin L, Chen D, Wang X, Caruso S, Kang JK, Amin AD, Wallace S, Dobie R, Yin D, Rodriguez-Fiallos OM, Yin C, Mehal A, Izar B, Friedman RA, Wells RG, Pajvani UB, Hoshida Y, Remotti HE, Arpaia N, Zucman-Rossi J, Karin M, Henderson NC, Tabas I, Schwabe RF. Filliol A, et al. Nature. 2022 Oct;610(7931):356-365. doi: 10.1038/s41586-022-05289-6. Epub 2022 Oct 5. Nature. 2022. PMID: 36198802 Free PMC article.
Distinguishing features of long COVID identified through immune profiling.
Klein J, Wood J, Jaycox JR, Dhodapkar RM, Lu P, Gehlhausen JR, Tabachnikova A, Greene K, Tabacof L, Malik AA, Silva Monteiro V, Silva J, Kamath K, Zhang M, Dhal A, Ott IM, Valle G, Peña-Hernández M, Mao T, Bhattacharjee B, Takahashi T, Lucas C, Song E, McCarthy D, Breyman E, Tosto-Mancuso J, Dai Y, Perotti E, Akduman K, Tzeng TJ, Xu L, Geraghty AC, Monje M, Yildirim I, Shon J, Medzhitov R, Lutchmansingh D, Possick JD, Kaminski N, Omer SB, Krumholz HM, Guan L, Dela Cruz CS, van Dijk D, Ring AM, Putrino D, Iwasaki A. Klein J, et al. Nature. 2023 Nov;623(7985):139-148. doi: 10.1038/s41586-023-06651-y. Epub 2023 Sep 25. Nature. 2023. PMID: 37748514 Free PMC article.
Dental Injuries and Management.
Reddy LV, Bhattacharjee R, Misch E, Sokoya M, Ducic Y. Reddy LV, et al. Facial Plast Surg. 2019 Dec;35(6):607-613. doi: 10.1055/s-0039-1700877. Epub 2019 Nov 29. Facial Plast Surg. 2019. PMID: 31783416
Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study.
Patil VM, Noronha V, Menon N, Rai R, Bhattacharjee A, Singh A, Nawale K, Jogdhankar S, Tambe R, Dhumal S, Sawant R, Alone M, Karla D, Peelay Z, Pathak S, Balaji A, Kumar S, Purandare N, Agarwal A, Puranik A, Mahajan A, Janu A, Kumar Singh G, Mittal N, Yadav S, Banavali S, Prabhash K. Patil VM, et al. J Clin Oncol. 2023 Jan 10;41(2):222-232. doi: 10.1200/JCO.22.01015. Epub 2022 Oct 20. J Clin Oncol. 2023. PMID: 36265101 Clinical Trial.
Patients were randomly assigned 1:1 to TMC consisting of oral methotrexate 9 mg/m(2) once a week, celecoxib 200 mg twice daily, and erlotinib 150 mg once daily, or TMC with intravenous nivolumab (TMC-I) 20 mg flat dose once every 3 weeks. ...
Patients were randomly assigned 1:1 to TMC consisting of oral methotrexate 9 mg/m(2) once a week, celecoxib 200 mg twice daily, and e …
Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial.
Noronha V, Joshi A, Patil VM, Agarwal J, Ghosh-Laskar S, Budrukkar A, Murthy V, Gupta T, D'Cruz AK, Banavali S, Pai PS, Chaturvedi P, Chaukar D, Pande N, Chandrasekharan A, Talreja V, Vallathol DH, Mathrudev V, Manjrekar A, Maske K, Bhelekar AS, Nawale K, Kannan S, Gota V, Bhattacharjee A, Kane S, Juvekar SL, Prabhash K. Noronha V, et al. J Clin Oncol. 2018 Apr 10;36(11):1064-1072. doi: 10.1200/JCO.2017.74.9457. Epub 2017 Dec 8. J Clin Oncol. 2018. PMID: 29220295 Clinical Trial.
Purpose Chemoradiation with cisplatin 100 mg/m(2) given once every 3 weeks is the standard of care in locally advanced head and neck squamous cell cancer (LAHNSCC). ...Patients and Methods In this phase III randomized trial, we assessed the noninferiority of cisplatin 30 m …
Purpose Chemoradiation with cisplatin 100 mg/m(2) given once every 3 weeks is the standard of care in locally advanced head and neck …
Targeting Epsins to Inhibit Fibroblast Growth Factor Signaling While Potentiating Transforming Growth Factor-β Signaling Constrains Endothelial-to-Mesenchymal Transition in Atherosclerosis.
Dong Y, Wang B, Du M, Zhu B, Cui K, Li K, Yuan K, Cowan DB, Bhattacharjee S, Wong S, Shi J, Wang DZ, Chen K, Bischoff J, Linton MF, Chen H. Dong Y, et al. Circulation. 2023 Feb 21;147(8):669-685. doi: 10.1161/CIRCULATIONAHA.122.063075. Epub 2023 Jan 2. Circulation. 2023. PMID: 36591786 Free PMC article.
Effect of Thromboprophylaxis on Clinical Outcomes After COVID-19 Hospitalization.
Wang TY, Wahed AS, Morris A, Kreuziger LB, Quigley JG, Lamas GA, Weissman AJ, Lopez-Sendon J, Knudson MM, Siegal DM, Kasthuri RS, Alexander AJ, Wahid L, Atassi B, Miller PJ, Lawson JW, Patel B, Krishnan JA, Shapiro NL, Martin DE, Kindzelski AL, Leifer ES, Joo J, Lyu L, Pennella A, Everett BM, Geraci MW, Anstrom KJ, Ortel TL; ACTIV-4C Study Group. Wang TY, et al. Ann Intern Med. 2023 Apr;176(4):515-523. doi: 10.7326/M22-3350. Epub 2023 Mar 21. Ann Intern Med. 2023. PMID: 36940444 Free PMC article. Clinical Trial.
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation.
Patil VM, Noronha V, Menon N, Singh A, Ghosh-Laskar S, Budrukkar A, Bhattacharjee A, Swain M, Mathrudev V, Nawale K, Balaji A, Peelay Z, Alone M, Pathak S, Mahajan A, Kumar S, Purandare N, Agarwal A, Puranik A, Pendse S, Reddy Yallala M, Sahu H, Kapu V, Dey S, Choudhary J, Krishna MR, Shetty A, Karuvandan N, Ravind R, Rai R, Jobanputra K, Chaturvedi P, Pai PS, Chaukar D, Nair S, Thiagarajan S, Prabhash K. Patil VM, et al. J Clin Oncol. 2023 May 1;41(13):2350-2361. doi: 10.1200/JCO.22.00980. Epub 2023 Jan 27. J Clin Oncol. 2023. PMID: 36706347 Clinical Trial.
Adult patients (age 18 years) with LAHNSCC planned for chemoradiation and an Eastern Cooperative Oncology Group performance status of 0-2 and who were cisplatin-ineligible were randomly assigned in 1:1 to either radiation alone or radiation with concurrent docetaxel 15 mg/m
Adult patients (age 18 years) with LAHNSCC planned for chemoradiation and an Eastern Cooperative Oncology Group performance status of 0-2 an …
443 results